stockrow
Friday 6 November 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
14.33
0.43
+3.09%
Follow BHVN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.75 | 6.68 | 4.28 | 2.57 | |
Current Ratio |
3.18 | 7.41 | 4.73 | 3.05 | |
Net Debt/EBITDA |
0.57 | 0.83 | 0.07 | (0.83) | |
Debt/Assets |
52.92% | 51.87% | 69.99% | 100.23% | |
Debt/Equity |
4.59 | 1.87 | 21.23 | (2.69) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.90 | 1.15 | 0.62 | 0.83 | |
Capex/Depreciation |
0.00 | 0.00 | (0.20) | (0.08) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.05 | 0.08 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.21) | (1.02) | (0.56) | (0.71) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.21) | (1.02) | (0.57) | (0.71) | |
Cash per Share |
2.97 | 2.36 | 1.78 | 1.07 | |
Shareholders Equity per Share |
0.48 | 0.88 | 0.08 | (0.65) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.48 | 0.88 | 0.08 | (0.65) | |
Free Cash Flow |
(130.67) | (149.92) | (85.55) | (107.03) | |
Working Capital |
252.40 | 333.57 | 233.90 | 128.75 | |
Capital Expenditures |
(0.01) | — | (0.45) | (0.18) | |
Net Current Asset Value |
(31.05) | 48.74 | (61.96) | (170.41) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
14.84 | 14.78 | 15.87 | 15.51 | |
Average Assets |
533.28 | 462.68 | 460.58 | 336.40 | |
Average Common Equity |
237.75 | 194.50 | 73.40 | (57.70) |
Columns are period end dates · fundamentals updated 2 Nov 2026